TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05744167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BFRT
Description: Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MDRT
Description: Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
Study: NCT06291909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Steps Program
Description: Participants in the intervention group will be given access to the Small Steps website. Small Steps website provides a visual representation of the participant's current use of time and allows for manipulation to demonstrate how small lifestyle changes may improve sleep and physical activity needs. The personal outcome goals selected by the participant will also feature on participant's dashboard within the Small Steps website as a reminder. Participants will be prompted through the first 12 weeks to add a new behaviour change each week and will receive support phone calls weekly. During the 12-week Maintenance Phase participants will be guided to maintain their new behaviour, with supportive phone calls being progressively reduced from fortnightly to monthly. At the completion of the 12 weeks, investigator support will be withdrawn. Maintenance of the new behaviour without support will then be assessed over 12 additional weeks in the Follow-Up phase.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator Program
Description: Participants will receive generic health advice only and it will not be individually tailored, nor will they receive weekly support phone calls during the first 12-weeks. Participants will receive no feedback or support in the Maintenance or Follow-Up phases.
Study: NCT04944173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
Study: NCT04905056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ablation therapy
Description: Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
Study: NCT05132764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microosteoperforations
Description: 2 inter radicular bone microosteoperforations using temporary anchorage device tip.
Study: NCT05452733

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: differences of behavior between sleepwalking and non sleepwalking patient
Description: movement registry done by camera when low intensity sound are send to patient during sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: differences of behavior between sleepwalking and non sleepwalking patient
Description: movement registry done by camera when low intensity sound are send to patient during sleep.
Study: NCT05300776

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: M-ROSE analysis
Description: The M-ROSE analysis process consists of 3 procudures.~1. Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion\<1%, columnar epithelial cell proportion \<5% .~2. Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils \> 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion\> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~3. Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds.
Study: NCT05971069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group1
Description: Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group2
Description: Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group3
Description: No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Study: NCT04789889

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: intraoperative radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: postoperative radiotherapy
Description: postoperative radiotherapy
Study: NCT06589271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cell suspension
Description: 2 \* 10\^7 cells (2ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total endoscopic extraction of lumbar nucleus pulposus
Description: hUC-MSCs are injected into the opposite side of the minimally invasive surgical site immediately after surgery, and the puncture needle remains for 1 minute after injection and then pull out to prevent cell suspension leakage
Study: NCT06663384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Augmented Reality technology in TKA compared to standard TKA
Description: Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of Augmented Reality technology in TKA compared to standard TKA
Description: Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
Study: NCT06665009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manually Opened and Device-Opened Ampoules
Description: this study is to evaluate the ampoule peeling device in terms of safety, ease of use, time efficiency, difficulty of operation, and user satisfaction among nurses when opening ampoule bottles of different capacities
Study: NCT05114031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FB101
Description: Microbial intervention using product FB101

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline water
Study: NCT04738799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-Last Meal Sequence
Description: Carbohydrates consumed last during mealtimes for 6 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-Last Meal Sequence
Description: Carbohydrates consumed last during mealtimes for 6 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-First Meal Sequence
Description: Carbohydrates consumed first during mealtimes for 6 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-First Meal Sequence
Description: Carbohydrates consumed first during mealtimes for 6 days
Study: NCT05507346

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cross over Device (PCD or Dayspring - alternate to first group)
Description: Cross over after three month of use and a month of washout period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross over Device (PCD or Dayspring - alternate to first group)
Description: Cross over after three month of use and a month of washout period
Study: NCT04944173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circulating Tumor DNA assay
Description: After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
Study: NCT05585840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback-based virtual reality game
Description: The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
Study: NCT06310616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin
Description: Loestrin will be administered.
Study: NCT05984589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE Personalized Self-Managament Training (PSMT)
Description: Along with patient education and internalization of self-determination, the RISE intervention focuses on replacing unhealthy habits with health-promoting habits. Ongoing practice and guidance in generating and enacting SMART (specific, measurable, achievable, realistic, and time-bound) health goals is the centerpiece of the RISE intervention. Working one-on-one with the PI, participants will set goals and develop practical strategies to establish sustainable healthy behavior (HB) change. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create lasting change. The 6-week intervention includes 2 in-person visits and 4 videoconference sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized Self-Managament Training (SSMT)
Description: Participants randomized to the control condition will receive 6 standardized sessions from one of the OT interveners, matched to the PSMT for setting. At these visits, participants will be presented with slides containing pre-specified, standardized didactic content about the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) healthy behavior recommendations (HBRs). We hypothesize that these visits will control for the effect of research participation and increased knowledge about HBRs, and that simply providing standardized didactic content as an intervention modality without any personalization will have negligible effects on participants' healthy behaviors (HBs), self-efficacy, or quality of life. Content will follow the WCRF/AICR HBRs. Weeks 1-2 will focus on physical activity; weeks 3-4 will focus on diet and alcohol, and weeks 5-6 will focus on weight management and generalized strategies for HB change.
Study: NCT04847674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-53275 Dose A
Description: subcutaneous (sc) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-53275 Dose B
Description: subcutaneous (sc) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching subcutaneous (sc) placebo injection
Study: NCT06122207

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: * Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:~  * Women: 1 capsule of probiotic per day for 12 weeks.~* Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:~  * Women:1 capsule of placebo per day for 12 weeks.~* Men: 1 capsule of placebo per day for 6-months.
Study: NCT05534763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IERGD
Description: A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.

Intervention type: OTHER
Group type: OTHER
Intervention: IER SUPPORT
Description: A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
Study: NCT06450990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGY-1601-VT
Description: Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGY-1601-VT
Description: Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo
Study: NCT05140902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-care Portable Perfusion Phantom (P4)
Description: P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
Study: NCT04751851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium duration withdrawal programme with ACT
Description: * 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long duration withdrawal programme with ACT
Description: * 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medium duration withdrawal programme without ACT
Description: 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Long duration withdrawal programme without ACT
Description: 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
Study: NCT04651660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Cochlear Implant System
Description: Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Cochlear Implant System
Description: Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way.
Study: NCT05123482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8205
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8205 and AZD2936 (Rilvegostomig)
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
Study: NCT04944173

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circulating Tumor DNA assay
Description: After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circulating Tumor DNA assay
Description: After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
Study: NCT05415163

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: vascular photobiomodulation
Description: application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vascular photobiomodulation
Description: application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
Study: NCT04835857

Intervention type: DEVICE
Intervention: ViTrack
Description: ViTrack is a continuous non-invasive wearable blood pressure cuff.

Intervention type: DEVICE
Intervention: Oscillometric BP Device
Description: Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.

Intervention type: DEVICE
Intervention: Auscultatory cuff
Description: The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
Study: NCT06265454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose atropine eye drops
Description: Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose atropine eye drops
Description: Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05638373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One shade universal composite
Description: A resin composite with new smart chromatic technology and chameleon effect. It has the ability to match the new lighter shade of the bleached teeth unlike the conventional composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid resin composite
Description: A conventional resin composite with multiple shades
Study: NCT04625751

Intervention type: OTHER
Intervention: CO2-enriched air
Description: To assess cardiovascular reactivity

Intervention type: OTHER
Intervention: CO2-enriched air
Description: To assess cardiovascular reactivity

Intervention type: OTHER
Intervention: CO2-enriched air
Description: To assess cardiovascular reactivity

Intervention type: OTHER
Intervention: Meal response test
Description: Meal response test to assess changes in splanchnic blood flow.

Intervention type: OTHER
Intervention: Meal response test
Description: Meal response test to assess changes in splanchnic blood flow.

Intervention type: OTHER
Intervention: Meal response test
Description: Meal response test to assess changes in splanchnic blood flow.
Study: NCT05626946

Intervention type: OTHER
Intervention: Observation
Description: Observation

Intervention type: OTHER
Intervention: Observation
Description: Observation